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The emergence and spread of antiviral drug-resistant viruses have been a worldwide chal-
lenge and a great concern for patient care. We report A4 antibody specifically recognizing
and binding to the mutant I223R/H275Y neuraminidase and prove the applicability of A4
antibody for direct detection of antiviral multidrug-resistant viruses in various sensing plat-
forms, including naked-eye detection, surface-enhanced Raman scattering-based immu-
noassay, and lateral flow system. The development of the A4 antibody enables fast, simple,
and reliable point-of-care assays of antiviral multidrug-resistant influenza viruses. In addition
to current influenza virus infection testing methods that do not provide information on the
antiviral drug-resistance of the virus, diagnostic tests for antiviral multidrug-resistant viruses
will improve clinical judgment in the treatment of influenza virus infections, avoid the
unnecessary prescription of ineffective drugs, and improve current therapies.
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Influenza is the leading cause of serious respiratory infections,which can lead to hospitalization and death. Traditionally, twotypes of antiviral drugs have been used in therapy: ada-
mantines and neuraminidase inhibitors (NAIs). However, ada-
mantine resistance among circulating influenza A viruses,
including the A/H1N1 2009 pandemic influenza virus, is already
prevalent worldwide due to increased selection pressure in the
presence of drug treatment. Thus NAIs remain the only antiviral
drugs (e.g., zanamivir1 and oseltamivir2) used in current clinical
settings3. Owing to its oral bioavailability and easy administra-
tion, oseltamivir has been the first choice for treating A/H1N1
2009 pandemic influenza virus infection and for inclusion in
pandemic antiviral stockpiles4. Unfortunately, the emergence of
oseltamivir-resistant variants, especially among A H1N1 viruses,
has been reported and has become a great concern for patient
care. In early clinical trials in the UK, resistance after oseltamivir
treatment has been reported in up to 27% of children infected
with A H1N1 viruses5,6. Moreover, approximately 25% of H5N1-
infected patients develop resistance after oseltamivir treatment,
leading to fatalities7. Early optimism was eventually dispelled by
the emergence of oseltamivir-resistant A H1N1 viruses even in
the absence of drug use and the spread of this resistance to the
epidemic A H1N1 viruses8–10.
In 2010, an isoleucine-to-arginine change at position 223
(I223R, N1 numbering) in the neuraminidase (NA) of A H1N1
virus isolated from an immunosuppressed child on prolonged
oseltamivir and zanamivir therapy was reported11. In contrast to
the frequently observed H275Y (N1 numbering) change, which
causes selective resistance to oseltamivir12,13, the I223R mutation
confers a phenotype resistant to both oseltamivir and
zanamivir14,15. In clinical cases, the I223R change has been found
mostly in combination with H275Y. This double mutation
(I223R/H275Y) in the NA of the 2009 pandemic H1N1 influenza
virus has been reported as an antiviral multidrug-resistant virus
for both zanamivir and oseltamivir11,16–19. In animal models and
in vitro studies, I223R/H275Y double-mutant virus has shown
high levels of resistance to oseltamivir and zanamivir, and the
combination of I223R with H275Y does not compromise the
replication capacity or transmissibility of the virus16,20. Con-
sidering that the oseltamivir and zanamivir is the two most widely
used drugs for the treatment of influenza virus, the diagnosis of
double-mutant viruses is critical21.
Commercially available rapid influenza diagnostic tests
(RIDTs) are immunoassays that utilize influenza virus-specific
antibody affinity for the presence of the influenza virus anti-
gens22. Although RIDT is easy to use, cost-effective, and can
efficiently diagnose and treat influenza viruses within short pro-
cessing times (minutes), RIDTs currently in use do not provide
information on the antiviral drug resistance of influenza viruses,
because antiviral drug-resistant influenza virus-specific antibodies
have not yet been developed. For the identification of antiviral-
resistant viruses, conventional plaque reduction assays23,24, DNA
sequencing of genes, and real-time polymerase chain reaction
(RT-PCR) have been used. However, these methods are time
consuming, labor intensive, expensive, and require highly trained
personnel25–28. In order to diagnose drug-resistant viruses in
immunoassays, it is priority to secure antibodies with high affinity
for binding to mutant viruses.
Here we develop a monoclonal antibody, A4, specific to I223R/
H275Y NA. According to the experimental and simulation
results, the binding affinity of A4 for oseltamivir- and zanamivir-
resistant mutant I223R/H275Y NA is approximately 600 times
stronger than its binding affinity for oseltamivir- and zanamivir-
susceptible wild-type (wt) NA. This difference in the binding
affinity of the A4 antibody for I223R/H275Y NA and wt NA
allows to develop several detection methods for antiviral
multidrug-resistant influenza viruses. First, the A4 antibody is
tested on a naked-eye detection using A4-gold nanoparticle (Au
NP) aggregation. Only in the presence of I223R/H275Y pH1N1,
color of A4-Au NPs changes from red to purple. Second, we apply
A4 antibody to the surface-enhanced Raman scattering (SERS)-
based immunoassay for I223R/H275Y viruses. The combination
of A4 antibody with SERS improves the detection limit of I223R/
H275Y virus to 1.5 plaque-forming units (PFU). Third, A4-based
lateral flow immunoassay (LFA) system is developed for the rapid
diagnosis of I223R/H275Y pH1N1. The developed LFA system
can identify I223R/H275Y pH1N1 even in the mixture with wt
pH1N1. Furthermore, we successfully detect the mutant viruses in
nasopharyngeal samples from patients, suggesting the practical
applicability of the A4-based LFA for the diagnosis of multidrug-
resistant influenza virus-infected patients. We anticipate that the
A4 antibody-based, rapid, simple, and efficient detection of
antiviral multidrug-resistant influenza viruses will prevent both
the unnecessary administration of ineffective drugs and the
spread of antiviral-resistant viruses due to continuous drug
administration.
Results
Production of A4 antibody. For the development of A4 antibody
specific to I223R/H275Y NA, we first prepared influenza virus
subtype H1N1 NA proteins, i.e., drug-susceptible wt NA and
oseltamivir- and zanamivir-resistant mutant I223R/H275Y NA.
These NAs were expressed in Spodoptera frugiperda (Sf9) cells
using a baculovirus expression system, purified, and confirmed by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) (Supplementary Fig. 1A) and western blot analysis
(Supplementary Fig. 1B). Previously, it has been reported that
I223R/H275Y NA exhibits an overall loose structure with dis-
turbed positions but with a local rearrangement of the compact
array at the drug-binding site19. The KI of I223R/H275Y NA for
oseltamivir was significantly increased by 7500 times compared to
that of wt NA due to the increase in the dissociation rate constant
(koff) for oseltamivir (15-fold)19. The KI of I223R/H275Y NA for
zanamivir was 22-fold greater than that of wt NA due to the
reduced association rate constant (kon) and increased koff18.
A monoclonal A4 antibody specifically recognizing I223R/
H275Y NA over wt NA was developed using a biopanning
protocol and a phage display library of fragment antigen bindings
(Fabs) against I223R/H275Y NA. Each round of panning
included a subtraction step against wt NA followed by panning
against I223R/H275Y NA to remove wt NA binders. After the
third and fourth rounds of panning, the enriched pool was
screened for I223R/H275Y NA-specific binders (Fig. 1a). Ran-
domly selected clones were subjected to soluble Fab expression
and screened by enzyme-linked immunosorbent assay (ELISA)
for their binding affinity to I223R/H275Y NA. Among them,
clone strongly bound to I223R/H275Y NA was selected and
subjected to DNA sequencing, which confirmed the presence of
unique clone (Fig. 1b). Immunoglobulin G (IgG) was converted
from the Fab form to the whole IgG form for further application
(Fig. 1c). IgG bivalency leads to binding affinities much higher
than those of Fabs through avidity effects29.
Binding of A4 antibody to I223R/H275Y NA protein. The
binding affinities of the purified whole antibodies to I223R/H275Y
NA protein were measured by ELISA. The selected A4 antibody
bound to I223R/H275Y NA in a concentration-dependent manner
with Kd of 3.50 nM (Supplementary Fig. 2A). Kd of A4 to wt NA
was 2.03 µM (Supplementary Fig. 2B), demonstrating the
approximately 600-fold tighter binding of A4 to I223R/H275Y NA
than to wt NA. The affinity and kinetics of the A4 binding
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interaction to I223R/H275Y NA was also determined by surface
plasmon resonance (SPR) (Fig. 2a). A4 was tested over a con-
centration range of 31.25–2000 nM on a low-density antigen-
coated chip. The kon and koff of A4 to I223R/H275Y NA were
2.84 × 103M−1 s−1 and 7.22 × 10−5 s−1, respectively; thus steady
state affinity (KD) was determined to be 0.254 nM. A4 was further
characterized for its binding specificity to I223R/H275Y NA
compared to wt NA using a dot-blot test by spotting different
amounts of I223R/H275Y and wt NA proteins on a nitrocellulose
(NC) membrane. The intensity of the dots corresponding to the
binding interaction between I223R/H275Y NA and A4 was sig-
nificantly stronger than that between wt NA and A4 (Fig. 2b, c).
In addition, we tested the recognition of single-mutant
influenza NA protein (H275Y NA) using A4 antibody. H275Y
mutation is the most frequently observed drug-resistant muta-
tion10. The A4 antibody bound to H275Y NA in a concentration-
dependent manner with Kd of 0.12 µM (Supplementary Fig. 3A).
Supplementary Fig. 3B displays the interaction between A4
antibody and pH1N1/H275Y mutant virus (107 PFUmL−1) by
dot-blot analysis. For the comparison, I223R/H275Y pH1N1 (107
PFUmL−1) and wt NA were also examined. As shown in
Supplementary Fig. 3B, the dot was observable only from the
double-mutant virus. This suggests the low affinity of A4
antibody to the single-mutant influenza virus.
Structural feature of A4 antibody and NA epitope. Although
three-dimensional (3D) structure of A4 has not been solved yet,
we found the G6 antibody specific for binding to vascular
endothelial growth factor (VEGF) as the structural template of A4
because the sequence identity amounts to 85.6% (Supplementary
Fig. 4). It has been reported that the root-mean-square deviation
between the experimental and the predicted structures has fell
within 1.5 Å when the sequence identity between the template
and the target exceeds 50%30. Figure 3a, b are the comparative
view of the docking poses of A4 in the wt NA and I223R/H275Y
NA. The calculated binding modes of the epitope models for wt
NA and I223R/H275Y NA reveal the different patterns for
complexation. The binding free energy of the A4–I223R/H275Y
NA complex is 1.8 kcal mol−1 lower than that of the A4–wt NA
complex, which is in agreement with the higher binding affinity
of the former than the latter. The wt NA appears to be stabilized
in complementarity-determining region (CDR) of A4 through the
hydrogen bonds with the backbone aminocarbonyl atom of
Asp101 in the heavy chain and with the side-chain carboxylate
group of Asp103 in the heavy chain (Fig. 3c). On the other hand,
the side-chain carboxylate ion of Glu100 and the two backbone
amidic moieties of Asn30 and Ser31 in the heavy chain are
involved in the hydrogen-bond stabilization of I223R/H275Y NA
in CDR of A4 (Fig. 3d). Judging from the structural features
derived with docking simulations, the higher binding affinity of
I223R/H275Y NA to A4 than the wt NA may be attributed in a
large part to the strengthening of the hydrogen-bond interactions
in the antibody–epitope complex. Remarkably, the side chain of
Leu224 of the wt NA is accommodated in a small hydrophobic
pocket comprising the light and heavy chains of CDR. As a
consequence of the double mutations, on the other hand, the
side-chain phenolic moiety of Tyr275 binds to the hydrophobic
pocket in the A4–I223R/H275Y NA complex instead of Leu224.
This van der Waals contact seems to be stronger than that in the
A4–wt NA complex because aromatic–aromatic hydrophobic
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Fig. 1 Selection of I223R/H275Y NA-specific monoclonal antibody. a Screening for the specificity of monoclonal phages from third round of panning by
ELISA. Each experiment was repeated two times independently with similar results. b Amino acid sequence of A4. c SDS-PAGE of purified A4 under
nonreducing (NR) and reducing (R) conditions. Each experiment was repeated three times independently with similar results. Lane M: protein marker; HC:
heavy chain, LC: light chain.
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Besides the increase in the number of hydrogen bonds, the
strengthening of hydrophobic interactions may also be invoked to
explain the higher binding affinity of the A4–I223R/H275Y NA
complex than the A4–wt NA counterpart.
Docking simulation results with mutational analysis. In order
to assess the importance of the hydrophobic interactions to sta-
bilize the epitopes in the CDR of A4, we carried out the muta-
tional analysis at positions His94 in the light chain and Trp33 in
the heavy chain. These mutant A4 antibodies were purified with
the same method as the wts. Supplementary Fig. 5 shows the
binding affinities of I223R/H275Y NA with respect to the two
kinds of mutant A4 antibodies (H94A and W33A mutant A4
antibodies). We note that the mutation of A4 antibody at position
94 in the light chain from His to Ala leads to approximately 50-
fold increase in the Kd value associated with binding of I223R/
H275Y NA (183 nM). This indicates the significant role of His94
in the light chain in the stabilization of the epitope. Similarly, the
Kd value of I223R/H275Y NA increases from 3.50 to 150 nM in
going from the wt to the W33A mutant in the heavy chain. The
results of mutational analyses are thus consistent with those of
docking simulations indicating that the strengthening of hydro-
phobic interactions with aromatic side chains are responsible for
tight binding of I223R/H275Y NA in the CDR of A4. Judging
from the consistency between the experimental and computa-
tional results, the capability of forming a van der Waals contact
with the aromatic residues in CDR seems to be a determinant for
selective binding to A4 antibody.
Application of A4 antibody to I223R/H275Y virus detection.
Development of bioreceptor is the key requirement of the bio-
sensor production. Until now, antiviral drug-resistant influenza
viruses were not routinely diagnosed because of the absence of the
proper bioreceptor. We found that the A4 antibody exhibited
highly increased binding capacity to the I223R/H275Y mutant
virus. Since A4 is the first discovered antiviral multidrug-resistant
influenza virus-specific antibody, it can be directly employed for
the development of multidrug-resistant virus diagnostic methods.
This prompted us to develop various kinds of I223R/H275Y
mutant virus-sensing methods by using A4 antibody as shown in
Fig. 4. First, A4 antibody was applied to the Au NPs to distinguish
I223R/H275Y pH1N1 with wt pH1N1 in the naked eye. In the
presence of I223R/H275Y pH1N1, color of A4-Au NPs changes
from red to purple. Second, SERS-based immunoassay for I223R/
H275Y mutant virus was demonstrated by using A4 antibody.
SERS is a fascinating phenomenon that significantly increases the
Raman signal of molecules in plasmonic hot spots. Since SERS
has been employed for the sensitive detection of viruses due to its
single-molecule sensitivity, the adoption of A4 in SERS-based
immunoassay enables the sensitive detection of mutant virus.
Third, A4-based LFA system was developed for the diagnosis of
I223R/H275Y pH1N1. LFA is easy to use, cost-effective, and can
diagnose influenza viruses rapidly, therefore A4-based LFA sys-
tem can be used for the practical diagnosis of I223R/H275Y
pH1N1 in real world.
A4-based colorimetric detection of I223R/H275Y virus. We
designed an A4-based colorimetric assay to directly detect I223R/
H275Y mutant virus in the naked eye. A4-Au NPs were generated
by conjugating Au NPs to A4 via Au-S bond formation. The
mean size of the A4-Au NPs was 28.5 ± 6.7 nm as determined by
dynamic light scattering (DLS). The Au NPs showed maximum
absorbance at 520 nm and were deep red in color. The A4-Au
NPs remained monodispersed in the aqueous phase and deep red
in color without aggregation (Supplementary Fig. 6A). As shown
in Fig. 5a, the color of the A4-Au NP solution obviously changed
from deep red to purple as the I223R/H275Y pH1N1 virus con-
centration increased because the A4-Au NPs aggregated owing to
the binding interaction between A4 and the I223R/H275Y NA of
the virus. Simultaneously, the ultraviolet (UV)–visible absorption
spectrum was redshifted, with the absorbance at 520 nm (Abs520)
gradually decreasing and that at 580 nm (Abs580) increasing
(Supplementary Fig. 6B). The presence of wt pH1N1 virus and
H275Y pH1N1 virus in the A4-Au NP reaction solutions caused
little change in color or absorption spectral shift (Fig. 5a and
Supplementary Figs. 6C and 7A). The absorbance ratio of these
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Fig. 2 Analysis of the antigen-binding activity of A4. a Affinity
determination of A4 by SPR. Each experiment was repeated three times
independently with similar results. b Specific interaction between A4 and
NA by dot-blot analysis. A4 was applied to wt NA and I223R/H275Y NA
dotted in a twofold dilution series (0.78–100 ngmL−1), and HRP-conju-
gated anti-human IgG Fc was applied for detection. Each experiment was
repeated three times independently with similar results. c The binding
activity of A4 by densitometric analysis. All ELISA values were obtained
from triplicate wells and are expressed as the mean. Error bars= standard
deviation (n= 3).
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concentrations for quantitative analysis as shown in Fig. 5b. At
maximum Abs580 and Abs520, the A4-Au NPs were purple-
colored aggregates and red-colored dispersed particles, respec-
tively. Thus, as the Abs580/Abs520 value increased, the solution
became increasingly purple, indicating more aggregation. The
Abs580/Abs520 values exhibited a linear correlation with the
I223R/H275Y pH1N1 virus concentration. Even with 102 PFU of
I223R/H275Y pH1N1 virus, the Abs580/Abs520 value was
approximately 0.7. This indicates that the oseltamivir- and
zanamivir-resistant I223R/H275Y pH1N1 virus can be detected
directly by the naked eye using the A4-Au NPs.
A4-based SERS detection of I223R/H275Y virus. For the SERS-
based immunoassay of I223R/H275Y pH1N1 virus, Au nanoplate










































Binding free energy = –19.2 kcal/mol
Fig. 3 Structural feature of A4 and NA epitope. Docked poses of the model epitopes for a wt NA and b I223R/H275Y NA in CDR of A4. Calculated
binding modes of the model epitopes for c wt NA and d I223R/H275Y NA in CDR of A4. The β-strands of A4 and carbon atoms of NA epitopes are
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Fig. 4 Application of A4 to I223R/H275Y virus detection. Schematic illustration of I223R/H275Y pH1N1 detection using A4 in various sensing platforms
including colorimetry, SERS, and LFA.
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and Au NP were selected as immune substrate and immunoprobe,
respectively. The single-crystalline Au nanoplates can be excellent
immune substrates due to their flatness and clean surfaces31. We
prepared the Au nanoplates as reported previously31 and immo-
bilized three cysteine-tagged protein G (Cys3-protein G) and A4
antibodies onto the Au nanoplates sequentially. Protein G can
bind to the Fc region of the antibodies and has been widely used to
immobilize the antibodies with optimal orientation. The immu-
noprobes were prepared by modifying the Au NPs with malachite
green isothiocyanate (MGITC) and hemagglutinin (HA) anti-
bodies simultaneously. MGITC is a well-known Raman reporter
and HA antibodies can bind to the both wt and mutant viruses.
For the detection of influenza viruses, the immune substrates were
reacted with I223R/H275Y pH1N1, wt pH1N1, or H275Y pH1N1,
and then the immunoprobes were reacted (Supplementary Fig. 8).
Figure 6a is the SERS-based immunoassay results for I223R/
H275Y pH1N1 (blue spectrum) and wt pH1N1 (black spectrum).
The number of both viruses is 1500 PFU. The SERS-based
immunoassay result for H275Y pH1N1 is shown in Supplemen-
tary Fig. 7B. When the sample includes I223R/H275Y mutant
virus, Au NPs on a nanoplate (NPs-on-plate) structures can be
constructed through the immunoreaction of A4-I223R/H275Y
pH1N1-HA. This NPs-on-plate architectures can provide sig-
nificantly enhanced SERS signals. In contrast, very weak SERS
signals were obtained when the sample has wt pH1N1 or H275Y
pH1N1, because A4 does not bind to the wt influenza virus or
single-mutant virus. This result was further confirmed by the
scanning electron microscope (SEM) measurements of NPs-on-
plate structures. Supplementary Fig. 9 shows the NPs-on-plate
structures, which we obtained from SERS spectra of Fig. 6a. The
immunoprobes were well assembled on the Au nanoplate without
aggregation after incubating in the mutant virus sample, whereas a
few NPs were present on the nanoplate after incubating in the wt
pH1N1 sample. Figure 6b shows the plot of 1175 cm−1 band
intensity versus the number of viruses. On increasing the number
of mutant viruses, the SERS intensity increased. However, the
intensities are negligible through the whole number of wt viruses.
The corresponding SEM images also agree well with the SERS
results (Supplementary Fig. 10). The numbers of immunoprobes
increased by increasing the concentration of mutant virus but a
few immunoprobes were observed regardless of the concentration
of wt pH1N1. By combining the developed A4 antibody and
SERS-based immunoassay, we could detect I223R/H275Y mutant
virus as low as 1.5 PFU.
A4-based LFA of I223R/H275Y virus. LFA, a most widely used
point-of-care testing format, allows the rapid, visual, and direct
analysis of targets with high specificity and sensitivity. Currently
available LFAs for influenza viruses do not provide information
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Fig. 5 Colorimetric detection of I223R/H275Y pH1N1 using A4. a Optical
images of A4-Au NPs in the presence of I223R/H275Y pH1N1 (upper
panel) and wt pH1N1 (lower panel). Each experiment was repeated three
times independently with similar results. b Plot of Abs580/Abs520 versus
the number of influenza virus. Data represent the average plus/minus
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Fig. 6 SERS-based detection of I223R/H275Y pH1N1 using A4. a SERS
spectra of MGITC obtained from NPs-on-plate structures in the presence of
I223R/H275Y pH1N1 and wt pH1N1. The number of both viruses is 1500
PFU. Each experiment was repeated ten times independently with similar
results. b Plot of 1175 cm−1 band intensity versus the number of influenza
virus. Data represent the average plus/minus standard deviation from ten
measurements.
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for multidrug-resistant influenza virus by employing A4 anti-
body. Briefly, A4-Au NPs were added to the conjugation pad, and
the capture antibody and goat anti-human IgG were immobilized
on the NC membrane as the test and control lines, respectively.
Therefore, two lines in the test indicate the presence of I223R/
H275Y pH1N1 virus. After the assembly of LFA components,
virus sample was applied to the sample pad. The antiviral-
resistant I223R/H275Y pH1N1 virus reacts and binds to A4-Au
NPs, and then the complex is captured by immobilized anti-
influenza A nucleoprotein IgG on the test line, resulting in a
positive signal. On the other hand, wt pH1N1 virus and H275Y
pH1N1 virus are not able to interact with A4-Au NPs; thus a
signal from the test line is not observed. Figure 7a and Supple-
mentary Fig. 7C are the micrographs of the LFAs after detection
of wt, double-mutant, and single-mutant viruses. When the
I223R/H275Y pH1N1 virus samples were applied, the red test
lines were observed clearly. Importantly, even in the cases of high
concentrations of wt pH1N1 virus (106 PFU) and H275Y virus
(106 PFU), only the control line was observed in the absence of
the I223R/H275Y pH1N1 virus. The sensitivity of A4-based LFA
for the detection of I223R/H275Y pH1N1 virus was tested at
various virus concentrations (106–102 PFU), and positive signals
were confirmed for samples containing 106, 105, 104, and 103 PFU
of I223R/H275Y pH1N1 virus in a concentration-dependent
manner. In addition, the dose effect of I223R/H275Y detection in
nasopharyngeal swab samples was demonstrated (Supplementary
Fig. 11). These results demonstrate that this A4-based LFA has a
high detection specificity depending on the dose of I223R/H275Y
pH1N1 virus, with an limit of detection (LOD) of 103 PFU per
test.
The diagnostic efficiency and specificity of the A4-based LFA
was further verified by treating a mixture of antiviral-susceptible
wt pH1N1 and oseltamivir- and zanamivir-resistant I223R/
H275Y pH1N1 viruses at various ratios under human nasal fluid
conditions (Fig. 7b). The total virus concentration was 1 × 104
PFU per test ( = 1 × 105 PFUmL−1), and virus-free buffer was
used as the control. As the concentration of I223R/H275Y pH1N1
virus decreased, the detection signal in the test line gradually
decreased from strong to weak. The signal from the test line was
observed even in a mixed sample containing a high concentration
of the wt pH1N1 virus (9 × 103 PFU) and a small concentration of
the I223R/H275Y pH1N1 virus (1 × 103 PFU). No signal was
observed in the test line for the sample containing only the wt
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Fig. 7 LFA of I223R/H275Y pH1N1 using A4. a Optical images of A4-based lateral flow systems after detection of I223R/H275Y pH1N1, wt pH1N1, and
control sample. b Optical images of A4-based lateral flow systems after detection of I223R/H275Y and wt pH1N1 mixture in nasal fluid and control sample.
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virus. These results demonstrate that A4-based LFA has a high
detection specificity depending on the dose of mutant I223R/
H275Y pH1N1 virus even in the mixture with wt virus, with an
LOD of 103 PFU per test. Considering that the RIDTs are mainly
performed by using the human nasal samples including small
amounts of mutant viruses and overwhelming amounts of wt
viruses, this result is quite impressive.
Finally, we investigated that the A4-based LFA can be used for
the diagnosis of multidrug-resistant influenza virus in real human
samples. Because the current diagnosis in the hospital does not
confirm the presence of antiviral drug resistance of influenza
viruses, nasopharyngeal samples from patients with influenza-like
symptoms were collected and mixed with I223R/H275Y pH1N1
virus (103 PFU). Figure 8a is an optical image of A4-based lateral
flow systems after detection of influenza-positive nasopharyngeal
swab samples in the absence of I223R/H275Y pH1N1 virus where
only the control line was observed. On the other hand, the red test
lines were observed clearly after detection of influenza-positive
nasopharyngeal swab samples in the presence of I223R/H275Y
pH1N1 virus (Fig. 8b). Totally, we tested 40 human nasophar-
yngeal swab samples (Supplementary Fig. 12). The sensitivity and
specificity of A4-based LFA developed for rapid antiviral
multidrug-resistant influenza virus diagnostic tests are 100%
(40/40) and 100% (40/40), respectively. According to the
guideline of National Institute of Food and Drug Safety
Evaluation of Korea, a minimum of 20 sample results are
required for approval of an in vitro diagnostic system. We also
tested the present mutant virus-sensing methods by using four
kinds of influenza virus subtypes (A/Puerto Rico/8/1934 (H1N1),
A/Brisbane/10/2007 (H3N2), A/swine/Korea/GC0503/2005
(H1N1), and A/canine/Korea/MV1/2012 (H3N2)). The virus
samples were prepared by mixing each of the I223R/H275Y
influenza viruses (103 PFU) with influenza-positive nasopharyn-
geal swab samples (n= 6). Figure 9 and Supplementary Fig. 13
are optical images of A4-based lateral flow system after detection
of influenza-positive nasopharyngeal swab samples in the
absence or presence of I223R/H275Y influenza viruses, in which
positive test lines were clearly observed in influenza-positive
nasopharyngeal swab samples taken with various subtypes of
I223R/H275Y influenza virus. Based on this result, we anticipate
that the A4-based LFA can be used for the rapid antiviral
multidrug-resistant influenza virus diagnostic test in near future.
Influenza-positive nasopharyngeal swab samples in the absence of I223R/H275Y pH1N1a
b Influenza-positive nasopharyngeal swab samples in the presence of I223R/H275Y pH1N1
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Fig. 8 LFA of I223R/H275Y pH1N1 in human nasal fluid samples using A4. Optical images of A4-based lateral flow systems after detection of influenza-
positive nasopharyngeal swab samples a in the absence or b presence of I223R/H275Y pH1N1 (103 PFU).
































































Fig. 9 LFA of I223R/H275Y influenza viruses in human nasal fluid
samples using A4. Optical images of A4-based lateral flow systems after
detection of influenza-positive nasopharyngeal swab samples in the
absence or presence of I223R/H275Y influenza viruses (A/Puerto Rico/8/
1934 (H1N1), A/Brisbane/10/2007 (H3N2), A/swine/Korea/GC0503/
2005 (H1N1), and A/canine/Korea/MV1/2012 (H3N2)).
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The accurate diagnosis of an infectious disease has a significant
impact on clinical decisions made in response to the disease. Drug
susceptibility testing prior to therapy will prevent drug abuse and
inhibit the spread of drug-resistant viruses. In this study, we
developed an A4 antibody specifically recognizing and binding to
the mutant I223R/H275Y NA and demonstrated that it is possible
to directly detect antiviral multidrug-resistant viruses in various
sensing platforms. We have verified the applicability of A4
antibody for the development of quantitative detection tools on a
variety of detection platforms, including naked-eye detection,
SERS-based immunoassay, and lateral flow system. The develop-
ment of the A4 antibody in this study enables fast, simple, and
reliable point-of-care assays of antiviral multidrug-resistant
influenza viruses. In addition to current influenza virus infection
testing methods, diagnostic tests for antiviral multidrug-resistant
viruses will improve clinical judgment in the treatment of
influenza virus infections, avoid the unnecessary prescription of
ineffective drugs, and greatly improve current therapies.
Methods
Materials. All chemicals were purchased from Sigma-Aldrich unless otherwise
specified. NA-FluorTM Influenza NA Assay Kit was purchased from Applied
Biosystems. Viral RNA Extraction Kit was purchased from Qiagen. Absorbent pads
(CFSP203000, cellulose fiber) and NC membrane (HF090MC100) were purchased
from Millipore. A polyester conjugate pad was purchased from Boreda Biotech.
Anti-influenza A virus nucleoprotein antibody were purchased from Abcam.
Influenza virus strains, including A/California/07/2009 (H1N1), A/Puerto Rico/8/
1934 (H1N1), and A/Brisbane/10/2007 (H3N2), were originally provided from the
Korea Centers for Disease Control and Prevention, Korea. A/swine/Korea/GC0503/
2005 (H1N1) and A/canine/Korea/MV1/2012 (H3N2) were kindly provided by
Professor Dae-Sub Song (Korea University). The pH1N1/H275Y mutant virus
(H275Y mutation A/Korea2785/2009 pdm: NCCP 42017) was obtained from the
National Culture Collection for Pathogens (NCCP) operated by the Korea National
Institute of Health. The titers of viruses were measured by an RT-PCR assay from
Promega according to the manufacturer’s instructions.
Virus propagation and clinical nasopharyngeal samples. Madin-Darby Canine
Kidney (MDCK) cells (ATCC CCL-34) were obtained from the American Type
Culture Collection (ATCC) (Rockville, USA). MDCK cells were cultivated in
Dulbecco’s Modified Eagle’s Media supplemented with 5% fetal calf serum. The
cells were infected with influenza virus strains, and the virus titer (PFU) was
determined in the presence of overlay media containing agarose and tosyl phe-
nylalanyl chloromethyl ketone–trypsin for 72 h at 37 °C and 5% CO2. The reverse
genetics system was used to generate different subtypes of the I223R/H275Y
influenza virus. The expression plasmids for the eight-plasmid reverse genetic
system were kindly donated by Dr. Meehyein Kim of Korea Research Institute of
Chemical Technology (Daejeon, Republic of Korea)32,33. NA and HA genes derived
from A/Puerto Rico/8/1934 (H1N1), A/Brisbane/10/2007 (H3N2), A/swine/Korea/
GC0503/2005 (H1N1), and A/canine/Korea/MV1/2012 (H3N2) genomic RNAs
were cloned individually into pVP-NA or pVP-HA vector using universal reverse
primers and genome-specific primers. In addition, I223R/H275Y mutation was
introduced within the NA fragment by the forward primer: 5′-TATTCGTCT
CAGGGATGAAGACTATCATTGCTTTGAGCTACATT-3′ and reverse primer:
5′-ATATCGTCTCGTATTTGTTTTTAATTAATGCACTCAAATGCAAA-3′.
Briefly, co-cultured 293T and MDCK cells (0.5 × 106 cells per well) grown in 6-well
plate were transfected using Lipofectamine 3000 (Thermo Fisher Scientific)
according to the manufacturer’s instructions (1 μg of each influenza DNA plas-
mid). After 6 h of incubation, the transfection medium was replaced by Opti-MEM.
After 30 h of transfection, each well was supplemented with 1 ml of Opti-MEM
containing 0.75 μg mL−1 tosylsulfonyl phenylalanyl chloromethyl ketone–trypsin.
At 3–6 days post transfection, cell supernatants were titrated onto MDCK cell
monolayers to estimate influenza virus titers. All experiments were done in
triplicate.
Nasopharyngeal samples from patients with influenza-like symptoms were
collected with the flocked nasopharyngeal swabs and placed into the virus transport
media (UTM, Copan Diagnostics Inc., USA). Each sample was analyzed with the
AdvanSure RV RT-PCR Kit (LG Life Sciences, Korea) following the manufacturer’s
instructions with the SLAN Real-Time Quantitative PCR Detection System (LG
Life Sciences, Korea). A Ct (threshold cycle) value of 25 was used for the cut-off for
influenza positivity according to the manufacturer’s recommendation. All samples
were stored at −70 °C before use. The protocol for this retrospective study was
reviewed and approved by the Institutional Review Board of Yonsei University
Health Service, Severance Hospital, Seoul, Korea (IRB approval number: 4-2017-
1179).
Expression and purification of recombinant protein. The wt NA and mutant NA
(I223R/H275Y) genes derived from A/H1N1 2009 pandemic influenza virus were
amplified by PCR. The PCR products were cloned into the pAcGP67A vector (BD
Biosciences) and transfected into the Sf9 insect cell line to produce recombinant
proteins. The culture medium was collected, clarified by centrifugation at 110 × g,
and subjected to further viral propagation. The cultured Sf9 cells were inoculated
with recombinant baculovirus at a multiplicity of infection of 10 and incubated at
27 °C for 96 h. The cells were collected after centrifugation, and the cell pellet was
resuspended in cell lysis buffer (50 mM Tris-HCl, pH 8.5, 5 mM 2-mercap-
toethanol, 100 mM KCl, 1 mM phenylmethylsulfonyl fluoride), sonicated, and
centrifuged at 16,000 × g for 15 min at 4 °C. After the cell lysate was sonicated to
reduce its viscosity, the cell debris was removed by centrifugation for 1 h at
16,000 × g. The soluble protein from the cell supernatant was applied to Ni-
nitrilotriacetic acid agarose resin (Qiagen), washed, and eluted with buffer (50 mM
Tris-HCl, 0.5 M NaCl, 0.5 M imidazole, pH 8.0). The purified proteins were dia-
lyzed against phosphate-buffered saline (PBS) and further purified by Q-Sepharose
anion-exchange chromatography (GE Healthcare).
A4 panning and screening. For antibody screening, large naive human antigen-
binding fragment phage display library (3 × 1010) in Korea Research Institute of
Bioscience and Biotechnology was used34. A phagemid vector (KRIBB-Fab) con-
tains a bicistronic operon under the control of LacZ promoter. Immunotubes
(Nunc) were coated with 100 μg of wt NA or I223R/H275Y NA overnight at 4 °C,
washed twice with PBS, and blocked with 4% skim milk in PBS at 37 °C for 1 h. The
antibody library phages were preincubated with wt NA at 37 °C for 2 h. The
subtracted phages were then incubated with I223R/H275Y NA at 37 °C for 1 h.
After washing with 0.05% Tween 20 in PBS (PBST), bound phages were eluted with
0.1 M glycine–HCl (pH 2.2) and neutralized with 2 M Tris base. The eluted phages
were amplified by infecting TG1 cells followed by superinfection with helper
phages (VCSM13)35. The amplified phages were then subjected to another round
of panning. Four rounds of panning were conducted, and the stringency of
selection was increased with each round by gradually increasing the number of
washes from 10 to 40.
To screen individual clones for specific binding to I223R/H275Y NA, 500
colonies were randomly selected from the output plate after the third or fourth
round of panning, cultured in Superbroth medium containing 100 μg mL−1
ampicillin until optical density of 0.5, and induced for Fab expression in
Escherichia coli TG1 cells at 30 °C overnight by adding isopropyl β-D-1-
thiogalactopyranoside to a final concentration of 1 mM. The culture supernatant of
each clone was subjected to ELISA to screen anti-I223R/H275Y NA antibodies. In
detail, a microtiter plate was coated with 100 ng of I223R/H275Y NA in coating
buffer (0.05 M carbonate buffer, pH 9.6) and incubated at 4 °C overnight. After
blocking, Goat F(ab′)2 Anti-Human IgG (Fab′)2-HRP (Abcam, 1:1000) antibody
was used for the colorimetric detection of bound clones using the
tetramethylbenzimidine substrate. Clones showing positive signals in ELISA were
subjected to DNA sequencing, and the nucleotide sequences of variable heavy
chain (VH) and variable kappa light chain (VK) regions were determined.
Expression and purification of whole IgG. To convert the selected Fabs into
whole IgG format, the VH and VK sequences were amplified by PCR and com-
bined with the leader sequences of IgG heavy and light chains, respectively, by
overlap extension PCR using Pfu DNA Polymerase (Thermo Scientific). The VH
and VK with leader sequences were sequentially cloned into the EcoRI-ApaI and
HindIII-BsiWI sites, respectively, in the antibody expression cassette (pdCMV-
dhfrC) containing the human constant region of γ1 heavy chain (Cγ1) and Cκ
gene36. For transient IgG expression, the resulting expression plasmid was intro-
duced into HEK293T cells using Lipofectamine (Invitrogen) according to the
manufacturer’s instructions, and the transfected cells were cultured in protein-free
medium (CD293, Invitrogen). The IgG was purified from the culture supernatant
by affinity chromatography on protein A (Millipore), and its expression and purity
were analyzed by western blotting and SDS-PAGE, respectively. The protein
concentration was determined by UV spectrophotometry (NanoDrop; Thermo
Fisher Scientific).
Enzyme-linked immunosorbent assay. Microtiter wells were coated with the
purified NA (100 ng) in 50 mM sodium carbonate buffer (pH 9.6) at 4 °C over-
night, blocked with bovine serum albumin (BSA) (2%) in PBS, and washed with
PBST. A reaction mixture containing purified antibody (10 nM) and various
concentrations (10−11–10−5 M) of NA as a competing antigen were preincubated
at 37 °C for 1–2 h. The mixture was then added to each well previously coated with
100 ng of NA. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG
(Pierce, 1:3000) was used for the detection of bound IgG. Color was developed with
the 3,3′,5,5′-tetramethylbenzidine substrate reagent set (BD Biosciences), and the
absorbance at 450 nm was measured using a microtiter plate reader (Emax;
Molecular Devices). Affinity was determined as the antigen concentration required
to inhibit 50% of binding activity and binding affinity (Kd) value was calculated
from a Klotz plot.
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SPR analysis. SPR experiments were performed to determine the binding affinity
between the target proteins and antibodies on a BIAcore 3000 (GE Healthcare). A4
antibody (7 µg mL−1) was covalently immobilized on sensor chip CM5 by standard
amine coupling protocol. Briefly, a mixture of 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (0.2 M) and N-hydroxysuccinimide (0.05 M) was injected onto the
chip at a flow rate of 5 μL min−1, and various concentrations of proteins (0–2000
nM) were injected across the sensor surface at flow rate 5 μLmin−1. Data were
fitted to a 1:1 Langmuir-binding model using the BIAevaluation software provided
by the manufacturer for the kinetic analysis.
Homology modeling of A4 antibody. 3D structure of A4 antibody was obtained
through the homology modeling with MODELLER program37 using the X-ray
crystal structure of the G6 antibody fragment specific for binding to VEGF38. G6
antibody served as a template for building the structure of A4 antibody suitable for
docking simulations with epitopes (Supplementary Fig. 4). During the homology
modeling, we adopted the conjugate gradient methods for structural optimizations
and the molecular dynamics simulations to minimize the violations of spatial
restraints. The atomic coordinates for the gap regions were optimized from a
randomized distorted structure to connect the two anchoring positions, as
implemented in MODELLER program. The loop structures were modeled with the
enumeration algorithm to enhance the accuracy of the predicted structure39.
Docking simulations of wt and I223R/H275Y NA in the CDR of A4. 3D
structure of A4 obtained in the precedent homology modeling served as the
receptor model in docking simulations with wt and I223R/H275Y mutant NA. The
epitope structures were extracted from the X-ray crystal structure of (PDB entry:
4B7R)40. Docking simulations were carried out using the AutoDock program to
estimate the binding free energy (ΔGbind) of the epitope in the CDR of A4, which












































The weighting parameters for van der Waals contacts (WvdW), hydrogen bonds
(Whbond), electrostatic interactions (Welec), entropic penalty (Wtor), and ligand
dehydration free energy (Wsol) were set to 0.1485, 0.0656, 0.1146, 0.3113, and
0.1711, respectively, as in the original AutoDock program. rij stands for the
interatomic distance, and Aij, Bij, Cij, and Dij are associated with the well depth and
the equilibrium distance in the potential energy function. The hydrogen bond term
has the additional weighting factor (E(t)) to describe the angle-dependent
directionality. To compute the electrostatic interaction energy between A4
antibody and the epitopes, we used the sigmoidal function with respect to rij
proposed by Mehler et al. as the distance-dependent dielectric constant42. In the
entropic penalty term, Ntor indicates the number of rotatable bonds in the epitope.
In the hydration free energy term, Si and Vi denote the atomic solvation energy per
unit volume and the fragmental atomic volume, respectively, while Occimax
represents the maximum occupancy of each atom in the epitope43. All the energy
parameters in Eq. (1) were extracted from the original AutoDock program to derive
the binding modes of wt and I223R/H275Y mutant NA in the CDR of A4.
Among 20 conformations generated with the genetic algorithm, those clustered
together had similar binding modes differing by <1.5 Å in positional root-mean-
square deviation. The lowest-energy configuration in the top-ranked cluster was
selected as the final structural models for antigen–antibody complexes.
Colorimetric detection of antiviral multidrug-resistant influenza virus. To
prepare A4-conjugated Au NPs, the A4 antibody (10 μg) was added to a mixture of
1 mL of a colloid of Au NPs and 0.1mL of borate buffer (0.1M, pH 8.5). After
incubation for 30min at room temperature, 0.1mL of 1% BSA was added to block
the surface of the Au NPs. After incubation for 60min at 4 °C, the conjugates were
collected by centrifugation at 16,000 × g for 15min at 4 °C. The final conjugates were
resuspended in deionized waster. The changes in size of the particles were confirmed
by using DLS (ELS-Z, Otsuka Electronics). The color change was observed and
measured using a multidetection microplate reader (Cytation 5, BioTek).
SERS-based detection of antiviral multidrug-resistant influenza virus. Au
nanoplates were synthesized in a horizontal hot-wall single-zone furnace system
with a 1-inch diameter inner quartz tube. The system was equipped with pressure
and mass flow controllers. In a quartz tube, an Au slug-containing alumina boat
was placed at the center of a heating zone. Before the reaction, the quartz tube was
purged with N2 gas for 30 min to maintain an inert atmosphere, and the pressure
was lowered to 5−10 Torr with a gas flow rate of 100 sccm. The Au slug-containing
alumina boat was heated to 1100−1170 °C, and the reaction time was 60−90 min.
During the reaction, Au vapor was transported by the carrier gas from the high-
temperature zone to the low-temperature zone, where substrates were present. For
the preparation of immune substrate, the Au nanoplates on silicon wafer were
incubated with 5 nM Cys3-protein G solution in PBS buffer for 12 h at 4 °C and
rinsed three times with 0.1× PBS. Cys3-protein G-modified Au nanoplates were
immersed in the 1 nM A4 antibody solution in PBS buffer for 12 h at 4 °C and
rinsed three times with 0.1× PBS. For the preparation of immunoprobes, 100 μL of
MGITC (1 μM in ethanol) solution was added to the Au NP solution to prepare a
1-mL solution. Next, the Au NP solution was incubated for 45 min at room
temperature with orbital shaking. Simultaneously, we mixed 10 μL of HS-(CH2)10-
NHS solution (10 μM in tetrahydrofuran) and 100 μL of HA antibody solution
(100 ng mL−1 in PBS) for 45 min at room temperature with orbital shaking. Fifty
microliters of the mixed solution was added to the prepared Au NP solution, and
this solution was incubated for 45 min at room temperature with orbital shaking.
After that, 1.15 μL of 1M Tris-HCl buffer (pH 6.8) was added to the Au NP
solution for 30 min at room temperature with orbital shaking. Finally, the Au NP
solution was centrifuged (19,800 × g) for 15 min and re-suspended in 0.1× PBS.
The I223R/H275 and wt viruses were diluted in PBS buffer with various
concentration and added to the prepared immune substrates for 6 h at 4 °C with
shaking. Then the immune substrates were rinsed three times with 0.1× PBS and
incubated in the prepared Au NP solution for 45 min at room temperature. After
washing with distilled water and drying with N2 gas, SERS spectra and SEM images
were obtained from the samples. SERS measurements were carried out using a
LabRAM HR system (HORIBA Jobin Yvon, France). The excitation source was
a He–Ne laser operating at λ= 633 nm, and the laser spot was focused on a sample
through a 50× objective lens. The SERS signals were recorded with a thermo-
dynamically cooled electron multiplying charge-coupled device (Andor) mounted
on a spectrometer with a 1200-groove mm−1 grating. SEM images were obtained
using a Nova230 system at an accelerating voltage of 15 keV.
LFA of antiviral multidrug-resistant influenza virus. The LFA test strip consists
of four components: a sample pad, an NC membrane, a conjugation pad, and an
absorbance pad. The sample pad was saturated with PBS solution containing 0.2%
Tween-20 and 1% (w/v) BSA. The sample pad was dried at room temperature and
stored in a desiccator for future use. The colloidal Au NP probes were added to the
conjugation pad, dried at room temperature for 2 h, and then stored in a desiccator.
The anti-influenza A nucleoprotein IgG (2 mgmL−1) and goat anti-human IgG
(1 mgmL−1) were immobilized on the NC membrane as the test and control lines,
respectively. After the NC membranes were dry, the membranes were blocked with
1% BSA. After all the components were assembled on the backing card, the test
strip was assembled on a strip cassette. During the assays, 150 μL of the sample was
directly applied to the sample pad, and this volume spread across the whole strip
within 5 min. The LFA was also evaluated in virus-containing 10% nasal fluid (Lee
Biosolution, Inc.) as well as in virus mixtures prepared by mixing double mutant
and wt viruses in a same way as described above. Lastly, the LFA was examined in
the influenza-positive nasopharyngeal swab samples.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
All data generated or analyzed during this study are included in this published Article
and its Supplementary Information files, and the source data underlying all figures and
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